Technology ID
TAB-4534
Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development
E-Numbers
E-218-2018-0
Lead Inventor
Emerson, Suzanne (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Co-Inventors
Nguyen, Hanh (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Torian, Udana
Applications
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Human Cell Lines
Lead IC
NIAID
The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.
Commercial Applications
The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus.
Competitive Advantages
The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes.
Licensing Contact: